Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

100.85 +1.58 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
From Mirum Pharmaceuticals
Via Business Wire
News headline image
Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02... 
Via Benzinga
News headline image
The Latest Analyst Ratings for Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Expectations for Mirum Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Analyst Expectations for Mirum Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals... 
Via Benzinga
News headline image
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou... 
Via Talk Markets
News headline image
Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in... 
Via Benzinga
News headline image
American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.